Harald Reinhart
Overview
Explore the profile of Harald Reinhart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
77
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jing S, Zhang Y, Lin Y, Gu X, Liu J, Guglietta A, et al.
Drugs R D
. 2024 Oct;
24(4):505-515.
PMID: 39368043
Background: Efgartigimod, a human immunoglobulin G (IgG)1-derived Fc fragment targeting the neonatal Fc receptor, has been developed into intravenous (IV) and subcutaneous (SC) formulations for treating generalized myasthenia gravis (gMG)...
2.
Wang K, Zhu Y, Xu F, Liu L, Liu L, Shi M, et al.
Eur J Pharm Sci
. 2024 Jan;
195:106713.
PMID: 38295963
Purpose: Omadacycline (PTK-0796) is a first-in-class aminomethylcycline for adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible pathogens. We investigated...
3.
Sinclair R, Sharifeh S, Thackwray S, Lickliter J, Wu J, Li J, et al.
Exp Dermatol
. 2023 Jun;
32(9):1538-1545.
PMID: 37377276
Interleukin (IL)-17A underlies the pathogenesis of chronic plaque psoriasis (CPP). Well-tolerated, effective IL-17A inhibitors for mild-to-moderate CPP are needed. ZL-1102 is a novel antibody fragment targeting IL-17A. To assess the...
4.
Kaye K, Shorr A, Wunderink R, Du B, Poirier G, Rana K, et al.
Lancet Infect Dis
. 2023 May;
23(9):1072-1084.
PMID: 37182534
Background: An urgent need exists for antibiotics to treat infections caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (ABC). Sulbactam-durlobactam is a β-lactam-β-lactamase inhibitor combination with activity against Acinetobacter, including multidrug-resistant strains....
5.
Yang H, Huang Z, Chen Y, Zhu Y, Cao G, Wang J, et al.
Front Pharmacol
. 2022 May;
13:869237.
PMID: 35529438
Omadacycline is a new type of aminomethylcycline antibiotic, having a broad antibacterial spectrum. But the pharmacokinetic characteristics and safety profile of the Chinese population remain unknown. It is also unclear...
6.
Dong D, Zheng Y, Chen Q, Guo Y, Yang Y, Wu S, et al.
Eur J Clin Microbiol Infect Dis
. 2020 May;
39(8):1559-1572.
PMID: 32356026
Antibiotic resistance of bacterial pathogens isolated in China is a major concern. Omadacycline is a novel tetracycline derivative that has been approved for use in skin infections and community-acquired pneumonia....
7.
Yang Q, Xu Y, Jia P, Zhu Y, Zhang J, Zhang G, et al.
J Antimicrob Chemother
. 2020 Apr;
75(7):1833-1839.
PMID: 32306049
Background: Durlobactam is a broad-spectrum inhibitor of class A, C and D β-lactamases. Sulbactam is a generic β-lactam most commonly used as a β-lactamase inhibitor in combination with ampicillin; however,...
8.
Datta R, Kramer E, Reinhart H, Campbell S, Wong E, Gupta S
Am J Med
. 2018 May;
131(11):1307-1309.
PMID: 29729234
No abstract available.
9.
Loose M, Naber K, Shields P, Reinhart H, Wagenlehner F
Int J Antimicrob Agents
. 2017 Nov;
51(3):422-426.
PMID: 29158143
Oral antibiotics for the treatment of urinary tract infections are scarce. In this ex vivo phase 1 annex study, the clinical safety, urinary concentrations and bactericidal activity of a new...
10.
Reinhart H, Hughson C, Ibarra de Palacios P
Trans R Soc Trop Med Hyg
. 2005 Feb;
99(4):315-6.
PMID: 15708392
No abstract available.